))
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
Manage episode 435688368 series 2843497
内容由The Lancet Group提供。所有播客内容（包括剧集、图形和播客描述）均由 The Lancet Group 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients.
Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
49集单集
分享
